Evidence map›Paper›PMID 18336926›Full record

ArticleAntiviral research2008

Effect of oral treatment with (S)-HPMPA, HDP-(S)-HPMPA or ODE-(S)-HPMPA on replication of murine cytomegalovirus (MCMV) or human cytomegalovirus (HCMV) in animal models.

Debra C Quenelle, Deborah J Collins, Latisha R Pettway, Caroll B Hartline, James R Beadle, W Brad Wan, Karl Y Hostetler, Earl R Kern

Abstract read
In one paragraph

Article in Antiviral research, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Review
  6. Antiviral drug resistance: mechanisms and clinical implications.Infectious disease clinics of North America · 2010
    Review
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Debra C QuenelleUniversity of Alabama School of Medicine, Birmingham, AL, USA. dquenell@uab.edu
Deborah J Collins
Latisha R Pettway
Caroll B Hartline
James R Beadle
W Brad Wan
Karl Y Hostetler
Earl R Kern

Funding

TREATMENT OF RETINOPATHY ASSOCIATED WITH AIDSR01EY007366 · NEI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI FREEMAN, WILLIAM R. · 1988 to 2013
$7.6M
Optimization of HPMPA and CDV Analogs for Treatment of SmallpoxR01AI074057 · NIAID · VETERANS MEDICAL RESEARCH FDN/SAN DIEGO · PI HOSTETLER, KARL Y · 2008 to 2011
$2.2M
ANALOGS OF HPMPA FOR TREATMENT OF SMALLPOXR01AI066499 · NIAID · VETERANS MEDICAL RESEARCH FDN/SAN DIEGO · PI HOSTETLER, KARL Y · 2005 to 2005
$1.4M
Lung-Targeted Poxvirus AntiviralsR21AI064615 · NIAID · VETERANS MEDICAL RESEARCH FDN/SAN DIEGO · PI HOSTETLER, KARL Y · 2005 to 2006
$571k
NEI NIH HHS EY-07366NEI NIH HHS R01 EY007366NIAID NIH HHS AI-064615NIAID NIH HHS AI-066499NIAID NIH HHS AI-074057NIAID NIH HHS N01 AI015439NIAID NIH HHS N01-AI-15439NIAID NIH HHS R01 AI066499NIAID NIH HHS R01 AI074057NIAID NIH HHS R21 AI064615
6 · The paper itself

Abstract

We utilized BALB/c mice infected with murine CMV (MCMV) or severe combined immunodeficient (SCID) mice implanted with human fetal tissue and infected with HCMV to determine the efficacy of (S)-9-[3-hydroxy-2-(phophonomethoxy)propyl]adenine ((S)-HPMPA), hexadecyloxypropyl-(S)-HPMPA (HDP-(S)-HPMPA) or octadecyloxyethyl-(S)-HPMPA (ODE-(S)-HPMPA). In MCMV-infected BALB/c mice, oral HDP-(S)-HPMPA at 30 mg/kg significantly reduced mortality when started 24-48 h post inoculation. In the experimental HCMV infection, oral administration of vehicle or 10mg/kg of (S)-HPMPA, HDP-(S)-HPMPA or ODE-(S)-HPMPA was initiated 24h after infection and continued for 28 consecutive days. Cidofovir (CDV), at 20mg/kg given i.p., was used as a positive control. HDP-(S)-HPMPA or ODE-(S)-HPMPA significantly reduced viral replication compared to vehicle-treated mice, while oral (S)-HPMPA was ineffective.

Indexed as

AdenineAdministration, OralAnimalsAntiviral AgentsCidofovirCytomegalovirusCytomegalovirus InfectionsCytosineHerpesviridae InfectionsLiverMiceMice, Inbred BALB CMice, SCIDMuromegalovirusOrganophosphonatesSurvival Analysis9-(S)-(3-hydroxy-2-(phosphonomethoxy)propyl)adenineAdenineAntiviral AgentsCidofovirCytosinehexadecyloxypropyl 9-(2-(phosphonomethoxy)propyl)adenineoctadecyloxyethyl 9-(3-hydroxy-2-(phosphonomethoxy)propyl)adenineOrganophosphonates

Identifiers

PMID18336926
PMCPMC2650230

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.